Moderators: mick
Search This Board: 
Created: 12/21/2005 01:56:04 PM - Followers: 20 - Board type: Free - Posts Today: 0


Turkey signed a deal with Sinovac for 50 million doses of the vaccine. The first three million doses are scheduled to arrive Monday in Turkey,
Mr. Koca said. Mr. Koca said Turkey would also get 4.5 million doses of the Pfizer-BioNTech vaccine by the end of March.
Around 1 million doses are expected to arrive at the end of January, he said.

CoronaVac, as Sinovac calls its vaccine, is made from killed coronaviruses. 
The method is one of the oldest ones for making vaccines,
used by Jonas Salk in the 1950s
to make a vaccine against polio.
After viruses are inactivated with chemicals,
they cannot make people sick,
but they can provoke the immune system to make antibodies that can provide long-term protection against live viruses.

Sinovac Biotech Ltd
  • Dec. 25, 2020

Turkish officials announced Thursday that a
vaccine from the Chinese company Sinovac has an efficacy rate of 91.25 percent,
but the finding was based on preliminary results from a small clinical trial and none of the data was published in a journal or posted online.

Updating 01-02-2021 FOR NEWS RELEASE 12-23-2020
1Globe Capital, the Largest Shareholder of Sinovac Biotech, Reached Agreement with SEC and Calls on All Stakeholders to Suppo...
December 23 2020 - 04:07AM

12-23-2020 I LIKE  to 'StockRoomBully' on 'Sinovac Biotech Ltd (SVA)'

1Globe Capital, the Largest Shareholder of Sinovac Biotech, Reached Agreement with SEC and Calls on All Stakeholders to Suppo...
December 23 2020 - 04:07AM
GlobeNewswire Inc.
 Share On Facebook

1Globe Capital LLC (“1GlobeCap”), a principal and long-term shareholder of Sinovac Biotech (NASDAQ: SVA) (“Sinovac”), 
has reached agreement with the Securities and Exchange Commission (“SEC”) to end investigation of its 13D form compliance.

During this critical phase of vaccine and therapeutics development for the ongoing pandemic, 
1GlobeCap felt it was important to focus on its many projects, 
which include the development of COVID-19 therapeutics and vaccines. 

For this reason, 1GlobeCap decided to accept a SEC settlement offer, in which 1GlobeCap neither admitted nor denied SEC findings.

Following Sinovac’s annual general meeting (“AGM”) on February 6th in 2018, 

the SEC investigated the reporting compliance of Sinovac shareholders. 1GlobeCap’s 13D/13G forms, 
prepared by legal experts at top US law firms, disclosed that: 

(1) 1GlobeCap held 22.4% of Sinovac shares; and 

(2) 1GlobeCap intended to support the dissident shareholder of Sinovac Beijing which proposed a competing offer to the insider-led buyout. 

1GlobeCap also communicated to Sinovac additional shares being held by its related parties. 

The SEC investigation staff on 13D compliance concluded that: 

(1) 1GlobeCap ’s ownership should also be inclusive of shares held by its related parties 
(in aggregate ~32.3% of all Sinovac shares); and 

(2) its 13D form should have been amended in a timely manner to 
include its participation in voting for an alternative slate of directors organized and nominated by other shareholders to replace 
the incumbent board. 

Before and since the settlement, 
SEC made no comments on the legitimacy of either the old or 
new boards and has not been involved in Sinovac’s internal corporate conflicts.

1GlobeCap has unequivocally protected all shareholder interests 
through its refusal to support any unfair buyout. 

When an insider buyout group attempted to take over Sinovac at a 
price below market value against the wishes of the majority of 

shareholders and adopted a “poison pill” strategy to preclude competing offers, 

1GlobeCap felt an obligation to adhere to its principles despite having been invited by the insider group to join them.

After over 90% of shareholders attending the AGM voted for a new board to prevent the takeover, 

the insider buyout group induced the outgoing board to 
"swallow" the poison pill to wrestle control at the expense of 
the company. 

This unprecedented move would have jeopardized years of progress 
and caused significant turmoil at the company. 

1GlobeCap’s success in obtaining injunctions in courts has prevented 
the retaliatory and unlawful implementation of the “poison pill” targeted all shareholders who voted against the re-election of the 
old board. 

Moreover, the “Status Quo Order” issued by the Delaware Court of Chancery against the 
“poison pill” effectively protected Sinovac’s normal operations regarding vaccine development.

In January 2020, 1GlobeCap’s Chairman had a productive meeting 
with Sinovac’s CEO at the company’s headquarters concerning paths forward for the company, 

importance of focusing on product development and offered its 
support to develop a vaccine against the novel coronavirus. Subsequently, 

there have been several follow up collaborative meetings between the two teams.

1GlobeCap, as the principal shareholder of Sinovac, 

calls on all Sinovac stakeholders to put aside their differences 
and work together to support Sinovac’s COVID-19 vaccine, 

which is a front-runner among global COVID-19 vaccine programs. 

Sinovac’s vaccine, if successful, could play a role in ending the pandemic, 
which transcends all the issues previously preventing collaboration among Sinovac shareholders.

About 1Globe Capital and Its Investment in Sinovac Biotech (Nasdaq: SVA)

1Globe Capital LLC focuses on investment in private and public 
companies in the healthcare and high-tech sectors.

1GlobeCap started to invest in Sinovac about 10 years ago. 

Previously, 1GlobeCap always voted to support Sinovac management 
and developed an amicable and collaborative relationship. 

The saga began in 2016 when Sinovac finally achieved success in developing its first major revenue generating product after many 
years of R&D financial loss. 

Certain venture capital funds together 
with certain Sinovac executives 
(“Insider Buyer”) proposed to privatize Sinovac. 

Another buyout group, led by PKV Sinobioway (“PKV”), offered a 
higher bid. 1GlobeCap, invited to join by both buyout groups, 
attempted to promote collaboration between the two buyout groups 
and requested a transparent and fair sale process. 

However, the board and management adopted a 
“poison pill” strategy to prevent competing offers and accepted 
a $7.0/share offer from the Insider 
Buyers while rejecting a $8.0/share offer from PKV. 

Frustrated investors, representing over 90% shareholders in attendance at the AGM, 

voted for a new board organized by PKV and nominated by 
OrbiMed Advisor LLC. Instead of a peaceful transition, 
the management used company funds 
(more than $20M according to company’s fillings) 
to hire US lawyers and consultants to litigate and retaliate against 
all shareholders voting against the re-election of the incumbent board. 

Since the AGM in February 2018, 
there has been no board elected by the majority of shareholders 
to protect their interests and the trading of Sinovac has been kept suspended by Sinovac.

Boston Address: One International Place, 44th Floor, Boston, MA, 02110, USA
Beijing Address: Block B, Techart Plaza, No.30 Xueyuan Road, Haidian District, Beijing, 100083, P.R. China

Contact: Stella Wang
Telephone: +86-10-62336199


Sinovac’s mission is to Supply Vaccines to Eliminate Human Diseases. 

To achieve these objectives, Sinovac focuses on research, development, manufacturing and marketing of human-use and animal-use vaccines. The Company also provides services for diseases control and prevention, collaborating with the Chinese governments at the national, state and local levels.

Years: --All--                2020                2019                2018                2017                2016                2015                2014                2013                2012                2011                2010                2009                2008                2007                2006                2005                  


Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial


  • Date: 2020-07-06

  • Pageview: 20017

BEIJING--Sinovac Biotech Ltd. ( “Sinovac” or the “ Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China,
today announced an update to its previously announced partnership with Butantan, a leading Brazilian producer of immunobiologic products and vaccines.


On July 3, 2020, the Brazilian National Regulatory Agency,
Anvisa, granted approval to a
phase III clinical trial sponsored by Instituto Butantan to test efficacy and safety of the inactivated COVID-19 vaccine developed by
Sinovac Life Sciences Co., Ltd. ( or “Sinovac LS”, previously known as Sinovac Research and Development Co., Ltd. or
“Sinovac R&D”), a wholly owned subsidiary of the Company, in Brazil.
This trial aims to be a pivotal study to support the licensure of this product.


Anvisa’s process review included manufacturing and clinical information generated by Sinovac,
and a clinical development plan and trial protocol developed by Butantan.
The agency fast-tracked the application due to the public health emergency which took approximately two weeks to conclude.
The review was conducted at the highest standards as Anvisa is a full member of the International Council for Harmonization of
Technical Requirements for Pharmaceuticals for Human Use (“ICH”)
and qualified as a full functional regulatory agency for the World Health Organization (“WHO”) prequalification process.


This study will recruit nearly 9,000 healthcare professionals working in COVID-19 specialized facilities in twelve clinical sites located in several states in Brazil.
The inclusion of participants is scheduled to start this month after ethical approval is obtained from each clinical site.


"The phase III clinical trial approval is a demonstration that the Sinovac and Butantan partnership is an efficient collaboration to move forward offering hope to save lives worldwide,"
commented Dr. Dimas Covas, Director of Instituto Butantan.


Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, “We are pleased to advance to Phase III trials with Butantan,
which will allow us one step further to our commitment to developing vaccines for global use and to our mission of supplying vaccines to eliminate human diseases.”


Sinovac LS initiated the development of an inactivated vaccine against COVID-19 (named CoronaVac) on January 28th, 2020.
Preclinical study results were published in the peer-reviewed academic journal Science.
On April 13th, 2020 the National Medical Products Administration (“NMPA”) granted approval to conduct phase I and II clinical trials in China.
The phase I and II trials commenced on April 16, 2020 in Jiangsu Province. China. A group of healthy adults aged 18-59 years old were vaccinated with a 0, 14 day schedule.
Preliminary phase I/II results were recently reported. There was no serious adverse event after vaccinating a total of 743 volunteers in the trials,
demonstrating a good safety profile for the vaccine candidate.
Over 90% seroconversion was observed in the phase II clinical trial 14 days after completion of a two-dose vaccination at day 0 and day 14.
A Phase II study on elderly adults is being conducted which will be followed by child and adolescent groups.
The phase II trial is expected to be completed at the end of 2020. The Company has partnered with several companies outside of China for phase III efficacy studies.


About Sinovac LS

Sinovac Life Sciences Co., Ltd., (or “Sinovac LS”), previously known as Sinovac Research & Development Co., td.,
is a research-based company incorporated in 2009 that conducts human vaccine research, development, manufacturing,
and sales. Sinovac LS is a wholly owned subsidiary of Sinovac Biotech (Hong Kong) Limited. It develops several human vaccines,
including vaccines against pneumonia, DTaP, Hib, hepatitis B vaccines and combo vaccines containing DTaP and Hib. Sinovac LS was granted 12 patents in vaccine technologies in China.
Sinovac Life Sciences is the developer of CoronaVac, an inactivated COVID-19 vaccine candidate,
and will be the marketing authorization holder of CoronaVac in China with a vaccine production license from China National Medical Products Administration (NMPA).


About Instituto Butantan

Instituto Butantan is the main producer of immunobiological products and vaccines in Brazil. Instituto Butantan carries out scientific missions
domestically and abroad through the Pan American Health Organization, the World Health Organization, UNICEF and the United Nations.
The Institute collaborates with other agencies of the São Paulo State Secretariat of Health and the Brazilian Ministry of Health for the
improvement of overall health in Brazil. It acts in partnership with various universities, research institutions, pharmaceutical companies,
and entities such as the Bill & Melinda Gates Foundation for the achievement of its institutional objectives.
For more information please visit the Institute website at http:// or contact the press office at (+55 11) 2627-9606 / 9428 or email to


About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research,
development, manufacturing and commercialization of vaccines that protect against human infectious diseases.
Sinovac’s product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza,
Quadrivalent Influenza vaccine (“QIV”), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella vaccine and mumps.
Healive, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017.
The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016.
In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine,
which it has supplied to the Chinese Government’s vaccination campaign and stockpiling program.
The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program.
The Company is developing a number of new products including a Sabin-strain inactivated polio vaccine,
pneumococcal polysaccharides vaccine, and a SARS-CoV-2 (commonly referred to as COVID-19) vaccine.
Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets.
The Company is registering its products in over 30 countries outside of China. For more information please see the
Company’s website at http://


Safe Harbor Statement

This announcement may include certain statements that are not descriptions of historical facts, but are forward-looking statements.
These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995.
These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements.
Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements.
In particular, the outcome of any litigation is uncertain, and the Company cannot predict the potential results of the litigation it filed or that could be filed against it by others.
Additionally, the triggering of a shareholder rights plan is nearly unprecedented, and the Company cannot predict the impact on the Company or its stock price should its rights plan have been triggered.




Sinovac Biotech Ltd.
Helen Yang
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910

ICR Inc.
Bill Zima +1-646-308-1707




*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.

ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.


PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
$SVA [PHASE-3 Sinovac COVID-19 Vaccine Collaboration with Butantan mick 07/20/2020 02:53:17 AM
Contact: Stella Wang mick 08/31/2022 06:40:25 PM
Contact: Stella Wang mick 08/31/2022 06:40:25 PM
#468 mick 08/31/2022 06:38:22 PM
#467 mick 08/31/2022 06:35:56 PM
Recent SVA News mick 08/31/2022 06:34:15 PM
SVA Sinovac Biotech Ltd mick 08/31/2022 06:33:45 PM
SVA Sinovac Biotech Ltd mick 07/17/2022 08:25:27 PM
#463 mick 07/15/2022 02:15:52 PM
#462 mick 07/15/2022 02:15:52 PM
never answered e-mail $SVA mick 07/15/2022 02:15:06 PM
yes hope it does $SVA mick 07/15/2022 02:14:34 PM
$SVA News: COVID-19-Impfstoff von SINOVAC erhält in Brasilien mick 07/15/2022 02:13:44 PM
$SVA News: SINOVAC COVID-19 Vaccine Is Authorized for mick 07/15/2022 02:13:34 PM
$SVA News: SINOVAC COVID-19 Vaccine Is Authorized for mick 07/15/2022 02:13:12 PM
Sinovac Biotech Ltd (SVA) mick 06/04/2022 03:37:23 PM
SINOVAC Reports Unaudited Second Half of 2021 Financial mick 05/01/2022 02:49:22 PM
Sinovac Biotech Ltd (SVA) mick 05/01/2022 02:48:58 PM
#453 mick 03/12/2022 04:16:54 PM
Sinovac Biotech Ltd (SVA) mick 03/12/2022 02:18:38 PM
$SVA News: NuScale Power and Spring Valley Acquisition mick 02/05/2022 05:38:03 PM
$SVA News: NuScale Power Announces Filing of a mick 02/05/2022 05:37:54 PM
#449 mick 01/02/2022 05:07:05 PM
#448 mick 12/11/2021 05:03:34 PM
Sinovac Biotech Ltd (SVA) mick 11/06/2021 12:28:11 PM
Sinovac Biotech Ltd (SVA) mick 10/08/2021 11:08:23 AM
#445 Sinovac Biotech Ltd (SVA) mick 09/22/2021 07:29:45 PM
#444 Sinovac Biotech Ltd (SVA) mick 08/14/2021 12:30:22 PM
#443 Sinovac Biotech Ltd (SVA) mick 07/10/2021 11:33:43 PM
#442 Some countries consider booster shots for those who mick 07/08/2021 02:10:56 PM
#441 Sinovac Biotech Ltd (SVA) mick 07/08/2021 02:10:30 PM
#440 WHO seeks more data on Sinovac Biotech’s COVID-19 mick 05/26/2021 11:46:46 AM
#439 SVA News: WHO seeks more data on Sinovac mick 05/26/2021 11:46:05 AM
#438 mick 05/02/2021 06:15:44 PM
#437 Sinovac vaccine 67% effective against symptomatic infection in mick 04/18/2021 12:36:23 PM
#436 Sinovac Biotech Ltd (SVA) mick 04/18/2021 12:35:52 PM
#434 RELATED 'Sinovac Biotech Ltd (SVA)' mick 02/20/2021 07:34:09 PM
#433 Sinovac’s COVID-19 vaccine is said to be effective mick 02/20/2021 07:31:35 PM
#432 Sinovac’s COVID-19 vaccine is said to be effective mick 02/20/2021 07:30:10 PM
#431 RADAR COULD START TO TRADE 'Sinovac Biotech Ltd (SVA)' mick 02/20/2021 07:29:32 PM
#430 Sinovac Biotech Ltd (SVA) mick 02/20/2021 07:29:06 PM
#429 TRADING STUFF $SVA mick 02/20/2021 07:28:56 PM
#428 Why is SVA halted? jonsmile 02/06/2021 08:59:31 PM
#427 $SVA TO MY SURPRISE $125-K ASK mick 01/31/2021 08:46:12 PM
#426 Wow! StockRoomBully 01/31/2021 08:42:47 PM
#425 YOU SEE RECENT ASK /////\\\\\ $125-K ????? mick 01/31/2021 08:14:55 PM
#424 N.Y. , NASDAQ mick 01/31/2021 08:14:09 PM
#423 Sinovac Biotech Ltd (SVA) mick 01/07/2021 08:24:34 PM
#422 $Sbmff StockRoomBully 01/03/2021 09:39:55 PM
#421 mick 01/03/2021 03:39:19 PM
#420 12-23-2020 I LIKE to 'StockRoomBully' on 'Sinovac mick 01/02/2021 05:37:16 PM
Post Subject